Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Tomoaki Ikeda"'
Autor:
Shintaro Maki, Sho Takakura, Makoto Tsuji, Shoichi Magawa, Yuya Tamaishi, Masafumi Nii, Michiko Kaneda, Kenta Yoshida, Kuniaki Toriyabe, Eiji Kondo, Tomoaki Ikeda
Publikováno v:
Biomedicines, Vol 12, Iss 4, p 804 (2024)
Fetal growth restriction (FGR) is a major concern in perinatal care. Various medications have been proposed as potential treatments for this serious condition. Nonetheless, there is still no definitive treatment. We studied tadalafil, a phosphodieste
Externí odkaz:
https://doaj.org/article/97f12b13eb44417497d28c193c2c40a0
Autor:
Makoto Tsuji, Shintaro Maki, Naosuke Enomoto, Kota Okamoto, Asa Kitamura, Shoichi Magawa, Sho Takakura, Masafumi Nii, Kayo Tanaka, Noriko Yodoya, Hiroaki Tanaka, Hirofumi Sawada, Eiji Kondo, Masahiro Hirayama, Tomoaki Ikeda
Publikováno v:
Medicina, Vol 59, Iss 5, p 900 (2023)
Background and Objectives: Tadalafil is expected to treat fetal growth restriction (FGR), a risk factor for stillbirth and neonatal morbidity. This study aimed to evaluate the fetal biometric growth pattern of fetuses with FGR treated with tadalafil
Externí odkaz:
https://doaj.org/article/1fda1711e6294b7a978d6a1a35cf3f0d
Autor:
Kayo Tanaka, Hiroaki Tanaka, Ryota Tachibana, Kento Yoshikawa, Takuya Kawamura, Sho Takakura, Hiroki Takeuchi, Tomoaki Ikeda
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 3, p 1474 (2022)
Fetal growth restriction (FGR) is a major cause of poor perinatal outcomes. Although several studies have been conducted to improve the prognosis of FGR in infants, no effective intrauterine treatment method has been established. This study aimed to
Externí odkaz:
https://doaj.org/article/f79c7a818ef74bfcb0acfac35eec6074
Autor:
Shintaro Maki, Ineko Kato, Naosuke Enomoto, Sho Takakura, Masafumi Nii, Kayo Tanaka, Hiroaki Tanaka, Shinsuke Hori, Kana Matsuda, Yukito Ueda, Hirofumi Sawada, Masahiro Hirayama, Akihiro Sudo, Tomoaki Ikeda
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 5, p 1448 (2020)
To assess the long-term effects of tadalafil, a therapeutic agent for fetal growth restriction (FGR), we evaluated the developmental progress of 1.5-year-old infants whose mothers had taken tadalafil during pregnancy. Twenty-four infants were assesse
Externí odkaz:
https://doaj.org/article/8b94335cdc3247c4b950f7fb83f491d7
Autor:
Hiroaki Tanaka, Shintaro Maki, Shoichi Magawa, Masafumi Nii, Kayo Tanaka, Kenji Ikemura, Kuniaki Toriyabe, Tomoaki Ikeda
Publikováno v:
Medicina, Vol 55, Iss 10, p 708 (2019)
Background and Objectives: Tadalafil for treatment of fetal growth restriction (FGR) or preeclampsia is given once a day orally. The drug kinetics of tadalafil were investigated to determine the ideal dosage to promote uterine blood flow. Materials a
Externí odkaz:
https://doaj.org/article/1fd0ca3229f6418786e4eff0bdb1df68
Autor:
Shintaro Maki, Hiroaki Tanaka, Makoto Tsuji, Fumi Furuhashi, Shoichi Magawa, Michiko K. Kaneda, Masafumi Nii, Kayo Tanaka, Eiji Kondo, Satoshi Tamaru, Toru Ogura, Yuki Nishimura, Masayuki Endoh, Tadashi Kimura, Tomomi Kotani, Akihiko Sekizawa, Tomoaki Ikeda
Publikováno v:
Journal of Clinical Medicine, Vol 8, Iss 6, p 856 (2019)
Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor with a long half-life, high selectivity, and rapid onset of action. Because the safety of using PDE5 inhibitors as therapeutic agents for fetal growth restriction (FGR) has been a problem worldwide,
Externí odkaz:
https://doaj.org/article/986dc5e2f8b24488a43f44cd70f92329
Autor:
Naosuke, Enomoto, Hiroaki, Tanaka, Shintaro, Maki, Sho, Takakura, Kayo, Tanaka, Shinji, Katsuragi, Tomoaki, Ikeda
Publikováno v:
Taiwanese Journal of Obstetrics and Gynecology. 61:230-233
In this study, the drug kinetics of tadalafil were compared between pregnant and non-pregnant women to determine the ideal dosage to promote uterine blood flow.We recruited five pregnant and five non-pregnant women, all of which were administered tad
Autor:
Hiroaki, Tanaka, Keiko, Koide, Masamitsu, Nakamura, Shintaro, Maki, Sho, Takakura, Naosuke, Enomoto, Kayo, Tanaka, Shinji, Katsuragi, Akihiko, Sekizawa, Tomoaki, Ikeda
Publikováno v:
The Journal of Maternal-Fetal & Neonatal Medicine. 35:9131-9135
The aim of this study was to measure the blood levels of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) before and after tadalafil treatment in patients with fetal growth restriction.Maternal blood was collected from 1
Autor:
Shintaro Maki, Hiroaki Tanaka, Sho Takakura, Masafumi Nii, Kayo Tanaka, Toru Ogura, Mayumi Kotera, Yuki Nishimura, Satoshi Tamaru, Takafumi Ushida, Yasuhiro Tanaka, Norihiko Kikuchi, Tadatsugu Kinjo, Hiroshi Kawamura, Mayumi Takano, Koji Nakamura, Sachie Suga, Michi Kasai, Osamu Yasui, Kenji Nagao, Yuka Maegawa, Tomomi Kotani, Masayuki Endo, Ichiro Yasuhi, Shigeru Aoki, Yoichi Aoki, Yoshio Yoshida, Masahiko Nakata, Akihiko Sekizawa, Tomoaki Ikeda
Publikováno v:
BMJ open. 12(6)
IntroductionTheTADAlafil treatment for Fetuses with early-onset growth Restriction: multicentrer, randomizsed, phase II trial (TADAFER II) study showed the possibility of prolonging the pregnancy period in cases of early-onset fetal growth restrictio
Autor:
Kayo Tanaka, Hiroaki Tanaka, Ryota Tachibana, Kento Yoshikawa, Takuya Kawamura, Sho Takakura, Hiroki Takeuchi, Tomoaki Ikeda
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 1474, p 1474 (2022)
International Journal of Molecular Sciences; Volume 23; Issue 3; Pages: 1474
International Journal of Molecular Sciences; Volume 23; Issue 3; Pages: 1474
Fetal growth restriction (FGR) is a major cause of poor perinatal outcomes. Although several studies have been conducted to improve the prognosis of FGR in infants, no effective intrauterine treatment method has been established. This study aimed to